Plus   Neg

Stock Alert: Cassava Sciences To Report Q4 Results Today

Cassava Sciences, Inc. (SAVA), a clinical-stage biotechnology company, that develops drugs for nervous system disorders, is scheduled to report its fourth-quarter results today, March 23.

On average, analysts polled by Thomson Reuters expect the company to report loss of $0.13 per share.

In the third-quarter, the company had a positive earnings surprise of $0.04 loss per share compared with loss per share of $0.13 during the corresponding period last year.

The company's lead drug candidate is PTI-125 proposed for the treatment of Alzheimer's disease is in phase IIb study. Cassava expects to announce top-line results by mid-year 2020.

Cassava is also developing PTI-125Dx, a blood-based diagnostic to detect and monitor Alzheimer's disease.

The company, as a rule, gives updates on clinical trials during quarterly results.

Cassava Sciences ended the third quarter with $17.8 million of cash and equivalents, and no debt.

SAVA was down $0.36 or 8.51% on March 20, before closing at $3.87. It has traded in the range of $1.00- $10.95 in the last 52-weeks.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
JPMorgan Chase CEO Jamie Dimon said it expects the bank's earnings to be "down meaningfully" in 2020 due to the disruptions created by coronavirus pandemic. He also noted that the U.S. was not adequately prepared for the pandemic. In his annual letter to the company's shareholders, Dimon said that the bank's board may consider suspending the dividend in an extremely adverse scenario. The U.S. Food and Drug Administration launched a national effort to facilitate the development of blood-related therapies to combat the ongoing coronavirus (COVID-19) pandemic. The FDA is focused on two investigational therapies derived from human blood called convalescent plasma and hyperimmune globulin, which are antibody-rich blood products made from blood donated by people who have recovered. Gilead Sciences Inc. said it is donating its existing supply of 1.5 million individual doses of remdesivir, its investigational medicine for coronavirus or Covid-19. The drug, which is yet to get regulatory approval, is available for compassionate use, expanded access and clinical trials to treat patients with the most severe symptoms of COVID-19.
Follow RTT